During the past decade, University Hospital of Ulm conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 5 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 4 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Hospital of Ulm" #1 sponsor was "University of Ulm" with 9 trials, followed by "Celgene" with 7 trials sponsored, "Scandion Oncology A/S" with 2 trials sponsored, "Abbott Medical Devices" with 1 trials sponsored and "Affimed GmbH" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Hospital of Ulm" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Alcedis GmbH" with 1 trials as a collaborator, "German Federal Ministry of Education and Research" with 1 trials as a collaborator, "Jazz Pharmaceuticals" with 1 trials as a collaborator and "National Center for Tumor Diseases, Heidelberg" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "University Hospital of Ulm" are "Acute Myeloid Leukemia" (5 trials), "Acute Myeloid Leukemia (AML)" (2 trials), "Acute Lymphoblastic Leukemia" (1 trials), "Amyotrophic Lateral Sclerosis" (1 trials) and "Aortic Valve Disease" (1 trials). Many other conditions were trialed in "University Hospital of Ulm" in a lesser frequency.

Most popular intervention types in "University Hospital of Ulm" are "Drug" (17 trials), "Procedure" (2 trials), "Device" (1 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Azacitidine" (2 trials), "Cytarabine" (2 trials), "Gemcitabine" (2 trials), "Placebo" (2 trials) and "SCO-101" (2 trials). Other intervention names were less common.

The vast majority of trials in "University Hospital of Ulm" are 24 trials for "All" genders.

Currently, there are NaN active trials in "University Hospital of Ulm". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in University Hospital of Ulm, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in University Hospital of Ulm, 7 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".